Kerry Mundt
Clinical Trial Assistant at Geron Corporation
Kerry Mundt's Professional Contact Details
Email (Verified)
****@geron.com
HQ
(650) 473-7700
Location
San Francisco, California, US
Company
Geron Corporation
Person Seniority
entry
Kerry Mundt's Current Company Details
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomeras...
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.
Public Symbol
GERN
Founded Year
1992
Organization Website
geron.com
Organization Languages
English
Organization Revenue
6200
Current Technologies
dns made easy
gmail
mimecast
google apps
office 365
google analytics
omniture adobe
mobile friendly
asp net
apache
telomerase inhibition
hematologic malignancies
oncology
biotechnology
biopharma
health diagnostics
hospital & health care
Kerry Mundt's Work History and Education
Geron Corporation
Clinical Trial Assistant
2010 - Present
Pharmacyclics, an AbbVie Company
Colleagues at Geron Corporation
Prospect on LinkedIn
Find emails on Linkedln, Sales Navigator, AngelList, CrunchBase, Google etc.
Download
Extension
Other people in our database: